Presbia (LENSF) 10-Q 10 Aug 18 2018 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2018	Aug. 10, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Trading Symbol	LENS
Entity Registrant Name	PRESBIA PLC
Entity Central Index Key	1,591,096
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		17,157,160

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Current assets
Cash	$ 3,328	$ 3,236
Accounts receivable	23	8
Inventory, net	71	127
Prepaid expenses and other current assets	305	108
Total current assets	3,727	3,479
Property and equipment, net	410	477
Intangible asset	1,411	1,479
Other assets	77	127
Total assets	5,625	5,562
Current liabilities
Accounts payable	471	628
Due to related parties	35	23
Note payable, current portion	482	480
Other current liabilities	744	1,151
Total current liabilities	1,732	2,282
Deferred rent	98	107
Due to related parties, net of current portion		12
Other liabilities, net of current portion	25	30
Total liabilities	1,855	2,431
Commitments and contingencies (note 7)
Shareholders' equity
Ordinary Shares $0.001 par value, 350,000,000 shares authorized; 17,157,160 and 17,121,857 shares issued and outstanding at June 30, 2018 and December 31, 2017	17	17
Deferred ordinary Shares €1.00 (US$1.35) par value, 39,994 shares authorized, issued and outstanding at June 30, 2018 and December 31, 2017	54	54
Additional paid-in capital	96,266	91,362
Accumulated deficit	(92,567)	(88,302)
Total shareholders' equity	3,770	3,131
Total liabilities and shareholders’ equity	5,625	5,562
Series A Redeemable Preferred Shares [Member]
Shareholders' equity
Preferred shares
USA Preferred Shares [Member]
Shareholders' equity
Preferred shares

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical)	Jun. 30, 2018$ / sharesshares	Jun. 30, 2018€ / sharesshares	Dec. 31, 2017$ / sharesshares	Dec. 31, 2017€ / sharesshares
Ordinary shares, par value | $ / shares	$ 0.001		$ 0.001
Ordinary shares, shares authorized	350,000,000	350,000,000	350,000,000	350,000,000
Ordinary shares, shares issued	17,157,160	17,157,160	17,157,160	17,157,160
Ordinary shares, shares outstanding	17,121,857	17,121,857	17,121,857	17,121,857
Deferred ordinary shares, par value | (per share)	$ 1.35	€ 1	$ 1.35	€ 1
Deferred ordinary shares, shares authorized	39,994	39,994	39,994	39,994
Deferred ordinary shares, shares issued	39,994	39,994	39,994	39,994
Deferred ordinary shares, shares outstanding	39,994	39,994	39,994	39,994
Series A Redeemable Preferred Shares [Member]
Preferred shares, par value | $ / shares	$ 0.001		$ 0.001
Preferred shares, shares authorized	50,000,000	50,000,000	50,000,000	50,000,000
Preferred shares, shares issued	100	100	0	0
Preferred shares, shares outstanding	100	100	0	0
USA Preferred Shares [Member]
Preferred shares, par value | $ / shares	$ 0.01		$ 0.01
Preferred shares, shares authorized	8,000	8,000	8,000	8,000
Preferred shares, shares issued	4,900	4,900	0	0
Preferred shares, shares outstanding	4,900	4,900	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Statement [Abstract]
Revenues	$ 3		$ 7	$ 5
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Cost of goods sold	$ 1	$ 17	$ 48	$ 28
Type of Cost, Good or Service [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Gross profit (loss)	$ 2	$ (17)	$ (41)	$ (23)
Operating expenses:
Research and development	974	2,022	1,684	3,863
Sales and marketing	360	816	712	1,777
General and administrative	894	1,649	1,756	3,403
Total operating expenses	2,228	4,487	4,152	9,043
Operating loss	(2,226)	(4,504)	(4,193)	(9,066)
Other expense	(10)		(10)
Interest expense	(10)	(4)	(19)	(18)
Loss before income tax provision	(2,246)	(4,508)	(4,222)	(9,084)
Income tax provision	5	25	43	41
Net loss	$ (2,251)	$ (4,533)	$ (4,265)	$ (9,125)
Net loss per ordinary share-basic and diluted	$ (0.13)	$ (0.27)	$ (0.25)	$ (0.58)
Weighted average shares outstanding - basic and diluted	17,079,548	16,956,056	17,042,358	15,618,001

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flow from operating activities:
Net loss	$ (4,265)	$ (9,125)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	126	171
Inventory provisions	45	29
Stock-based compensation	8	1,038
Loss on disposition of fixed assets	9
Imputed interest expense	21	40
Changes in operating assets and liabilities:
Accounts receivable	(15)	(7)
Inventory	11	24
Prepaid expenses and other current assets	(196)	(100)
Other assets	50	(2)
Accounts payable and other current liabilities	(747)	698
Income taxes payable	69	39
Deferred rent	(9)	58
Due to related parties	12	10
Net cash used in operating activities	(4,881)	(7,127)
Cash flow from investing activities:
Purchases of intangible assets	(2)	(87)
Purchases of property and equipment		(7)
Net cash used in investing activities	(2)	(94)
Cash flow from financing activities:
Proceeds from issuance of ordinary shares from rights offering, net of costs		10,485
Proceeds from issuance of preferred shares, net of costs	4,994
Net cash provided by financing activities	4,994	10,485
Net increase in cash	111	3,264
Effect of exchange rate on cash	(19)	71
Cash balance at beginning of period	3,236	7,333
Cash balance at end of period	$ 3,328	$ 10,668

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Basis of Presentation	(1) Basis of Presentation Principles of Consolidation. The accompanying consolidated financial statements have been derived from the historical cost basis of the assets and liabilities, financial condition and cash flows of Presbia PLC and Presbia Ireland, Limited, both organized in Ireland, Presbia Investments, a wholly-owned subsidiary of Presbia PLC organized in the Cayman Islands, and Presbia Ireland, Limited’s subsidiaries, Presbia Deutchland GmbH, Presbia USA, Inc., and OPL, LLC. Presbia Deutchland GmbH is organized in Germany, and Presbia USA, Inc. and OPL, LLC are both entities organized in the United States, and include Presbia USA, Inc.’s subsidiaries, Visitome, Inc. and PresbiBio, LLC, both organized in the United States, and OPL, LLC’s direct and indirect subsidiaries, PIP Holdings, C.V and Presbia Cooperatief U.A., both organized in the Netherlands, and PresbiOptical LLC, organized in the United States (collectively, including Presbia PLC, the “Company”). The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The Company’s fiscal year ends on December 31. The entities presented in the consolidated financial statements have been under common control during the periods presented. All intercompany accounts have been eliminated in consolidation. Basis of Presentation. The accompanying unaudited consolidated financial statements as of June 30, 2018 and for the three and six months ended June 30, 2018 and 2017, respectively, have been prepared in accordance with United States generally accepted accounting principles (“U.S.GAAP”) for interim financial reporting, and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The accompanying consolidated balance sheet at December 31, 2017 has been derived from the audited consolidated balance sheet at December 31, 2017, contained in the annual report on Form 10-K for the year ended December 31, 2017. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements presented in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Securities and Exchange Commission on March 30, 2018. In the opinion of management, the accompanying consolidated financial statements reflect all adjustments which are necessary for a fair presentation of the results of operations and cash flows for the periods presented. The results of operations for such interim periods are not necessarily indicative of results of operations to be expected for the full year. References to amounts in the consolidated financial statement sections are in thousands, except per share data, unless otherwise specified. Liquidity At June 30, 2018, the Company has an accumulated deficit of $92.6 million and it expects to incur significant additional future operating losses. As it continues to incur losses, the Company’s transition to profitability will depend on the successful development, approval and commercialization of its microlens. The Company may never achieve profitability, and unless and until it does, it will need to continue to raise additional capital. Based on the Company’s current business plan, management believes that its cash and cash equivalents at June 30, 2018 will not be sufficient to meet its anticipated cash requirements during the twelve-month period subsequent to the issuance of the financial statements included in this Quarterly Report on Form 10-Q. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date this Quarterly Report on Form 10-Q is filed with the U.S. Securities and Exchange Commission (SEC). The Company’s current commercialization strategy is targeted to countries where the Company can establish the market for its technology. This commercialization strategy will undergo continual prioritization and in the future the Company may adjust its commercialization efforts to preserve its existing cash or realize better results than anticipated which could have a positive impact on cash. The Company’s U.S. pivotal clinical trial and planned FDA approval is its highest priority. The Company must raise additional capital to fund its operations. It plans to raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements. Additional funds may not be available when the Company needs them on terms that are acceptable to the Company, or at all. If adequate funds are not available on acceptable terms, the Company may be required to delay, reduce the scope of, or curtail, its operations. To the extent that the Company raises additional funds by issuing equity securities, its shareholders will experience dilution, and debt financing, if available, may involve restrictive covenants.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(2) Summary of Significant Accounting Policies During the six months ended June 30, 2018 there have been no changes to the Company’s significant accounting policies as described in the Annual Report on Form 10-K for the fiscal year ended December 31, 2017, other than the adoption of the new revenue recognition standard noted below. Revenue Recognition Prior to 2018, we recognized revenue when there is persuasive evidence that an arrangement exists with our customers, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Revenue was recognized upon shipment and payments are either received in advance, or net 30 days for lenses or net 14 days for accessories. Distributor arrangements included certain perfunctory acceptance provisions and a one-year warranty, from the date of shipment, that products are free from defects in material workmanship. Under such provisions customers may reject shipments via written notifications ranging from 14-45 days or exchange defective product under warranty for the same non-defective product. We have not had any significant rejected shipments or warranty claims. We did not grant price concessions to our distributors. In 2012, we changed our commercialization strategy from exclusively using distributors to also targeting refractive laser centers equipped with femtosecond lasers, except in countries that require the use of distributors or sales representatives. In December 2017, in light our re-ordering of operational priorities, we have focused our commercialization and clinical trial efforts outside of the U.S. in Germany and South Korea, including established ophthalmic clinics in those countries. We recognize revenue from laser centers and ophthalmic clinics based upon an analysis of the terms of each customer arrangement and upon determination that persuasive evidence of an arrangement exists, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Revenues from laser centers and ophthalmic clinics during the three and six months ended June 30, 2018 and 2017 were not material. Effective January 1, 2018, the Company adopted the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), using the modified retrospective transition method. Under this method, the Company recognizes revenue based on an analysis of the goods and services provided to our customers in the ordinary course. We analyze all commercial agreements to identify (i) contracts and arrangements with customers that meet the criteria for revenue recognition under the new standard (ii) identify all performance obligations under the contractual arrangement, such as the delivery of our Microlens to our customers and any other deliverable(s) as defined in a commercial arrangement (iii) the determination of the transaction price and the allocation of such pricing over the defined contractual obligations in the contract with the customer and (iv) the recognition of revenue once the customer has assumed control over the contractual obligations. Control refers to the ability on the part of the customer to obtain substantially all the benefits of possession of the delivered product or service. Foreign Currency The functional currency of subsidiaries outside the United States of America is the U.S. Dollar. Transactions in foreign currencies during the year are re-measured at rates of exchange on the dates of the transactions. Gains and losses related to re-measurement of items arising through operating activities are accounted for in the statement of operations and comprehensive loss and included in general and administrative expense. Aggregate foreign exchange gains and losses are included in the Condensed Consolidated Statement of Operations. Aggregate foreign exchange gain was $28,000 for the three months ended June 30, 2018, and aggregate foreign exchange loss was $24,000 for the six months ended June 30, 2018. Aggregate foreign exchange loss was $52,000 and $79,000 for the three and six months ended June 30, 2017, respectively. Comprehensive Loss Comprehensive income or loss is defined as a change in equity of a company attributable to all transactions excluding those transactions resulting from investment with owners and distributions to owners. There were no differences between net loss and comprehensive loss in the three and six months ended June 30, 2018 and 2017 . Future Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 will be effective for the Company in the first quarter of 2019. ASU 2016-02 will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Although the Company is currently evaluating the full impact of ASU 2016-02 on its consolidated financial statements, upon adoption of ASU 2016-02 the Company anticipates that its operating leases will be recognized on the balance sheet as a lease liability if certain criteria is met, with a corresponding right of use asset. In February 2018, the FASB issued ASU 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220)—Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. This update was issued to address the income tax accounting treatment of the stranded tax effects within other comprehensive income due to the prohibition of backward tracing due to an income tax rate change that was initially recorded in other comprehensive income. This issue came about from the enactment of the Tax Cuts and Jobs Act on December 22, 2017, which changed the Company’s income tax rate from 35% to 21%. The ASU changed current accounting whereby an entity may elect to reclassify the stranded tax effect from accumulated other comprehensive income to retained earnings. The ASU is effective for periods beginning after December 15, 2018, although early adoption is permitted. The Company does not anticipate that the adoption of this ASU will have a material impact on its consolidated financial statements. In June 2018, the FASB issued ASU No. 2018-07, Compensation — Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. The new standard expands the scope of Topic 718 to include all share-based payment transactions for acquiring goods and services from nonemployees. ASU No. 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which the grantor acquires goods and services to be used or consumed in its own operations by issuing share-based payment awards. ASU NO. 2018-07 also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under ASC 606. ASU No. 2018-07 will be effective for the Company beginning after December 15, 2019, with early adoption permitted, but no earlier than the Company’s adoption of ASC 606. The Company is currently assessing the potential impact of adopting this guidance on its consolidated financial statements. Recent Accounting Standards In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The new standard is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 became effective for the Company in the first quarter of 2018 and allowed for full retrospective or a modified retrospective adoption approach. The Company adopted this new standard in January 2018 and it did not have a material adjustment on its consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows In October 2016, the FASB issued ASU. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other than Inventory. In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting,

Loss per Share

Loss per Share	6 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Loss per Share	(3) Loss per Share Basic net loss per ordinary share is calculated by dividing net loss allocated to ordinary shareholders by the weighted average number of ordinary shares outstanding during the reporting period, excluding unvested restricted stock awards. Diluted net loss allocated to ordinary shareholders per share is calculated based on the weighted average number of Ordinary Shares and dilutive potential Ordinary Shares outstanding during the period. Dilutive potential ordinary shares consist of the shares issuable upon the exercise of options and upon the vesting of restricted shares under the treasury stock method. In net loss periods, basic and diluted net loss per share are identical since the effect of potential ordinary shares is anti-dilutive and therefore excluded. Basic and diluted loss per share for the three and six months ended June 30, 2018 and 2017 were calculated as follows: Three-Months Ended June 30, Six-Months Ended June 30, 2018 2017 2018 2017 Net Loss $ (2,251 ) $ (4,533 ) $ (4,265 ) $ (9,125 ) Weighted average shares outstanding - basic and diluted 17,079,548 16,956,056 17,042,358 15,618,001 Net loss per ordinary share - basic and diluted $ (0.13 ) $ (0.27 ) $ (0.25 ) $ (0.58 ) Antidilutive securities, which consist of options and unvested restricted shares that are not included in the diluted net loss per share calculation, consisted of an aggregate of 1,049,795 and 1,152,500 weighted average shares for the three months ended June 30, 2018 and 2017, respectively and 972,019 and 1,050,000 for the six months ended June 30, 2018 and 2017, respectively.

Equity Based Awards

Equity Based Awards	6 Months Ended
	Jun. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Equity Based Awards	(4) Equity Based Awards Equity Issued by Presbia PLC Presbia Incentive Plan On January 14, 2015, the Company approved a compensation incentive plan (the “Presbia Incentive Plan”). The Presbia Incentive Plan permits the Company to grant awards of options, restricted shares, share appreciation rights, restricted share units, performance shares, performance share units, dividend equivalent rights in respect of awards and other share-based and cash-based awards, including annual and long-term cash incentive awards. A total of 2,200,000 ordinary shares are authorized for issuance under the Presbia Incentive Plan of which approximately 367,591 were available on June 30, 2018 for future grants and awards. The exercise price of each option award shall be determined by the Board of Directors (or a committee thereof) at the date of grant in accordance with the terms of the 2005 Plan, and under the Presbia Incentive Plan awards generally vest 20% annually over a five-year period and expire no later than 10 years from the grant date. The Presbia Incentive Plan terminates on January 14, 2025, unless terminated earlier by the board of directors. Awards under the Presbia Incentive Plan may be granted to employees, directors, consultants and other persons who perform services for the Company or a subsidiary of the Company. The following table shows share-based compensation expense based upon all equity awards issued by Presbia PLC included in the Consolidated Statements of Operations for the three and six months ended June 30, 2018 and 2017. The Company recorded a credit of $86,000 and $524,000 as a result of the reversal of stock-based compensation for participants whose relationship with the Company terminated in the three and six months ended June 30, 2018, respectively. Three-Months Ended June 30, Six-Months Ended June 30, 2018 2017 2018 2017 Research and development $ (49 ) $ 126 $ (227 ) $ 242 General and administrative 174 311 175 641 Sales and marketing 30 78 60 155 $ 155 $ 515 $ 8 $ 1,038 Options The following table sets forth the Company’s option activity for the six months ended June 30, 2018: Number of Presbia PLC Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance, January 1, 2018 849,100 $ 9.77 — Granted 365,000 $ 2.38 — Exercised — — — Forfeited/cancelled/expired (71,450 ) $ 9.38 — Balance, June 30, 2018 1,142,650 $ 7.44 — Vested, June 30, 2018 726,150 $ 9.82 — Non Vested, June 30, 2018 416,500 $ 3.27 — Exercisable, June 30, 2018 726,150 $ 9.82 — Employee Options The Company utilizes the Black-Scholes valuation model for estimating the fair value of granted stock options with the following assumptions in addition to the closing price of the Company’s ordinary shares on the date of the grant: (i) the Company estimates the expected term of the option utilizing the simplified method because of its limited history of option exercise activity and its options meet the criteria of a "plain-vanilla" option as defined by the Securities Exchange Commission (ii) due to its limited stock price volatility history, the Company uses a peer group average as permitted under Accounting Standards Codification (“ASC”) 718 consistent with the expected term of the stock option at the time of the grant and (iii) applies a risk-free interest rate based on the U.S. Treasury securities yield consistent with the expected term of the option at the time of the grant. The simplified method calculates the expected term as the average of the weighted average vesting period and contractual terms of the award. For those options granted to employees, stock-based compensation expense was based upon the fair value of the option as of the grant-date and attributed to future reporting periods on a straight-line basis over the vesting period, or the requisite service period. The Company adopted ASU 2016-09 on January 01, 2018, electing to account for forfeitures when they occur. The Company issued 365,000 and 0 employee options during the three and six months ended June 30, 2018. Options granted in 2018 vest 20% annually over a five-year period and expire 6.75 years from the grant date. The Company did not issue employee options during the three and six months ended June 30, 2017. Non-Employee Options During the three and six months ended June 30, 2018 and 2017, the Company did not grant options to non-employee consultants and medical advisors. In contrast to the determination of the fair value of options granted to employees, which are determined based upon the grant-date assumptions and applying the Black-Scholes model, the fair values for non-employee options and the related stock-based compensation expense are remeasured each financial reporting period based upon the assumptions applicable on the dates in which the financial statements are prepared, which are disclosed in the following table: Three-Months Ended June 30, Six-Months Ended June 30, 2018 2017 2018 2017 Stock price per share $0.85 - $1.13 $1.25 - $1.63 $0.85 - $1.95 $1.25 - $2.51 Expected term 6.6 - 7.1 Yrs. 7.7 - 8.4 Yrs 6.6 - 7.4 Yrs. 7.7 - 8.6 Yrs Volatility 72.9% - 77.3% 79.1% - 83.5% 72.9% - 77.3% 79.1% - 90.0% Dividends — — — — Risk-free rate 2.8% 2.2% 2.6% - 2.8% 2.2% - 2.3% Because the performance criteria of these grants is based solely upon a requisite service period, but are subject to forfeiture if the service conditions are not met, stock-based compensation expense is determined by a straight-line attribution of the remeasured expense (mark-to-market) over the requisite service period subject to an adjustment to previously recognized expense in the event forfeitures occur. Restricted Shares . The Company awarded 23,255 ordinary shares to the head of the Company’s medical advisory board as compensation for services provided during the six-month period ended June 30, 2018. The number of shares was determined by the closing price of $2.15 on June 29, 2018. The following table sets forth the Company’s restricted share activity for the three and six months ended June 30, 2018: Unvested Number of Shares Weighted Average Fair Value per Share Balance, December 31, 2017 134,367 $ 3.78 Granted 23,255 2.15 Vested (104,731 ) 3.02 Forfeited/cancelled — — Unvested, June 30, 2018 52,891 $ 5.45 Restricted Share Units During the three and six months ended June 30, 2018, the Board of Directors did not award restricted share units (“RSU” or “RSU’s” or “RSU Plan”) to officers and employees in accordance with the guidelines provided by the Presbia Incentive Plan, which includes a provision that the recipient must be employed as a condition of vesting. The Presbia RSU Plan authorizes the issuance of 20% of each recipient’s total RSU award for the first occurrence that the closing price of the Company’s ordinary shares exceed, for a period of 20 consecutive business days, price thresholds of $10.00, $15.00, $20.00, $25.00 and $30.00, respectively. The RSU Plan also provides for a one-year “wait” or service period prior to any vesting permitted under the plan. The RSU Plan has a seven-year expiration period following the date of the grant. Fair value of the RSU’s awarded are determined using a Monte Carlo Simulation (“MCS”) methodology, which considers the separate probabilities that each of the price thresholds or market conditions will be achieved under the RSU Plan guidelines. Each probability is weighted by its respective price threshold, or its intrinsic value, which provides the basis for an aggregate fair value. The Company used the following key inputs in determining the fair value using the MCS model: (i) the volatility of the entity’s common stock and (ii) the closing price of the entity’s stock as of the measurement date of the RSU award. In accordance with GAAP, the Company recognizes as stock-based compensation expense, using a straight-line attribution method, the aggregate fair value over future periods based upon the respective derived service periods and fair values for each of the price thresholds as provided by the MCS model. The following table sets forth the Company’s RSU activity for the six months ended June 30, 2018: Unvested Number of Shares Weighted Average Fair Value per Share Balance, December 31, 2017 739,000 $ 2.09 Granted — — Vested — — Forfeited/cancelled (226,000 ) 2.44 Unvested, June 30, 2018 513,000 $ 1.32 Unrecognized Share-based Compensation As of June 30, 2018 and 2017, there were $785,000 and $2,740,000, respectively, of unrecognized compensation expense related to employee and non-employee options of the Company, which collectively is expected to be recognized by the Company over the weighted average vesting period of 2.3 and 1.7 years, respectively. Unrecognized compensation expense for the same periods related to restricted shares was $226,000 and $290,000, respectively, and is expected to be recognized over the weighted average vesting periods of 1.8 and 1.5 years, respectively. As of June 30, 2018 and 2017, there was approximately $513,000 and 7,710,000 of unrecognized compensation expense with respect to the RSU’s over a weighted average remaining derived service period of 0.9 and 2.4 years, respectively.

Concentration of Credit Risk

Concentration of Credit Risk	6 Months Ended
	Jun. 30, 2018
Risks And Uncertainties [Abstract]
Concentration of Credit Risk	(5) Concentration of Credit Risk The Company had cash of $3.3 million and $3.2 million as of June 30, 2018 and December 31, 2017, respectively, which consists of checking account deposits. The Company maintains cash balances at financial institutions located in the United States and secured by the Federal Deposit Insurance Corporation up to $250,000. As of June 30, 2018, the Company was not authorized to manufacture or sell any of its products or services within the United States and, as a result, all of the Company’ revenues are derived from foreign customers. With respect to suppliers for the microlens, the Company had a five-year supplier agreement that expired in January 2017 with a lens manufacturer in Israel from which the Company received 100% of its lens supply for use in commercial activities outside the United States. The Company also has its own manufacturing facility in Irvine, California that the Company believes will be sufficient to supply lenses for commercial activities outside the United States once existing inventory is utilized, as well as in the United States, pending FDA approval.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	(6) Income Taxes Deferred income tax assets and liabilities are recognized for temporary differences between financial statement and income tax carrying values, using tax rates in effect for the years such differences are expected to reverse. Due to uncertainties surrounding the Company's ability to generate future taxable income and consequently realize such deferred income tax assets, a full valuation allowance has been established. The Company continues to maintain a full valuation allowance against its deferred tax assets as of June 30, 2018. The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more likely than not to be sustained upon audit by the relevant tax authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. In December 2017, the Company recorded a liability of $199,000 with respect to unpaid Irish income taxes in accordance with ASC 740-10, , Accounting for Uncertainty of Income Taxes, and increased that liability during the six months ended June 30, 2018 to $274,000. The Company’s policy is to recognize interest expense and penalties related to income tax matters as a component of the income tax provision. As of June 30, 2018 and December 31, 2017, the Company had $35,000 and $39,000, respectively, of tax related accrued interest and penalties on its consolidated balance sheet or on its consolidated statement of operations. A reconciliation of gross unrecognized tax benefits is as follows: June 30, 2018 December 31, 2017 Balance at the beginning of the year 199,000 — Increases related to current year tax positions 75,000 199,000 Balance at the end of the year $ 274,000 $ 199,000

Equity Transaction with Related

Equity Transaction with Related Party	6 Months Ended
	Jun. 30, 2018
Class Of Stock Disclosures [Abstract]
Equity Transaction with Related Party	(7) Equity Transaction with Related Party Private Placement with Related Party On April 12, 2018, Presbia PLC, its wholly-owned subsidiary, Presbia USA, Inc. and Richard Ressler, a member of Presbia PLC’s board of directors and its majority stockholder, entered into a Stock Purchase Agreement pursuant to which Mr. Ressler purchased in a private placement offering 100 preferred shares of the Company, with the rights set forth in the Subscription Letter, dated April 12, 2018, and 4,900 shares of preferred stock of Presbia USA for an aggregate purchase price of $5.0 million. Upon closing the offering, Mr. Ressler received a warrant to purchase 1,953,125 ordinary shares of Presbia PLC at an exercise price of $2.56 per share, subject to adjustments as provided under the terms of the warrants. The warrant is exercisable for five years from the issuance date and it contains a cashless exercise provision. The preferred shares of Presbia PLC and Presbia USA carry a one times liquidation preference. The preferred shares are redeemable upon a liquidation event in which all classes of equity holders are entitled to receive the same form of consideration and are redeemable at any time at our sole election, provided that a majority of the independent directors approve such redemption. The preferred shares accrue a dividend at the rate of 10% per annum during the first 18 months, 20% for months 19 through 24 and 30% from month 25 until such preferred shares are redeemed, payable in preferred shares on a quarterly basis. Undeclared dividends for the period from the date of issuance of April 12, 2018 to June 30, 2018 is 50,334 preferred shares of the Company. As long as the preferred shares remain outstanding, neither the Company nor its subsidiary shall take the following actions, without obtaining the prior consent of the holder of the preferred shares: (a) effect any alteration, repeal, change or amendment of the rights, privileges or preferences of the preferred shares in a manner that adversely affects the rights, privileges or preferences of those shares or any series thereof; (b) amend, modify or repeal any provision of the organizational documents in a manner that adversely affects the powers, preferences or rights of the preferred shares; (c) agree to any debt financing in an amount in excess of $8,000,000 (such amount being the maximum amount payable by the company under the debt instruments); (d) execute a guarantee; (e) effect any restructuring or liquidation; (f) settle any lawsuit or civil investigation requiring the payment of more than $1,000,000; or (g) execute any document or enter into any arrangement that has a potential liability to the Company in excess of $1,000,000. In addition, Presbia PLC guaranteed Presbia USA’s payment of the redemption price and any accrued and unpaid dividends with respect to the preferred shares issued by Presbia USA.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2018
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	(8) Commitments and Contingencies In May 2012, the Company entered into a five-year non-cancelable lease for office and manufacturing space in Irvine, California that was renewed on June 1, 2016 and provided for an extension of five consecutive years starting from the original lease expiration date of May 31, 2017 through May 31, 2022. The Company maintains a one-year lease (which is now month to month) in Dublin, Ireland that commenced on December 1, 2013. In February 2018, it terminated a 30-month lease in Amsterdam, the Netherlands, that commenced on January 1, 2016. This termination was based on a mutual agreement with the landlord. In December 2017, the Company vacated one of its Irvine, California locations and consolidated its operations into another location in Irvine. At December 31, 2017, a liability of $222,000, representing the fair value of the remaining lease obligation over the remaining 33 months was recorded as part of the short-term portion of deferred rent in the Consolidated Balance Sheet. During the six-month period ended June 30, 2018, the Company sublet the facility and settled the remaining lease obligation. Aggregate rent expense for the three months ended June 30, 2018 and 2017 was $113,000 and $168,000, respectively, and for the six months ended for the same period was $208,000 and $337,000, respectively. From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. Management does not believe that the outcome of any of these matters will have a material effect on the Company’s consolidated financial operations .

Subsequent Event

Subsequent Event	6 Months Ended
	Jun. 30, 2018
Subsequent Events [Abstract]
Subsequent Event	(9) Subsequent Event None

Basis of Presentation (Policies

Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation. The accompanying consolidated financial statements have been derived from the historical cost basis of the assets and liabilities, financial condition and cash flows of Presbia PLC and Presbia Ireland, Limited, both organized in Ireland, Presbia Investments, a wholly-owned subsidiary of Presbia PLC organized in the Cayman Islands, and Presbia Ireland, Limited’s subsidiaries, Presbia Deutchland GmbH, Presbia USA, Inc., and OPL, LLC. Presbia Deutchland GmbH is organized in Germany, and Presbia USA, Inc. and OPL, LLC are both entities organized in the United States, and include Presbia USA, Inc.’s subsidiaries, Visitome, Inc. and PresbiBio, LLC, both organized in the United States, and OPL, LLC’s direct and indirect subsidiaries, PIP Holdings, C.V and Presbia Cooperatief U.A., both organized in the Netherlands, and PresbiOptical LLC, organized in the United States (collectively, including Presbia PLC, the “Company”). The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The Company’s fiscal year ends on December 31. The entities presented in the consolidated financial statements have been under common control during the periods presented. All intercompany accounts have been eliminated in consolidation.
Basis of Presentation	Basis of Presentation. The accompanying unaudited consolidated financial statements as of June 30, 2018 and for the three and six months ended June 30, 2018 and 2017, respectively, have been prepared in accordance with United States generally accepted accounting principles (“U.S.GAAP”) for interim financial reporting, and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The accompanying consolidated balance sheet at December 31, 2017 has been derived from the audited consolidated balance sheet at December 31, 2017, contained in the annual report on Form 10-K for the year ended December 31, 2017. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements presented in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Securities and Exchange Commission on March 30, 2018. In the opinion of management, the accompanying consolidated financial statements reflect all adjustments which are necessary for a fair presentation of the results of operations and cash flows for the periods presented. The results of operations for such interim periods are not necessarily indicative of results of operations to be expected for the full year. References to amounts in the consolidated financial statement sections are in thousands, except per share data, unless otherwise specified.
Liquidity	Liquidity At June 30, 2018, the Company has an accumulated deficit of $92.6 million and it expects to incur significant additional future operating losses. As it continues to incur losses, the Company’s transition to profitability will depend on the successful development, approval and commercialization of its microlens. The Company may never achieve profitability, and unless and until it does, it will need to continue to raise additional capital. Based on the Company’s current business plan, management believes that its cash and cash equivalents at June 30, 2018 will not be sufficient to meet its anticipated cash requirements during the twelve-month period subsequent to the issuance of the financial statements included in this Quarterly Report on Form 10-Q. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date this Quarterly Report on Form 10-Q is filed with the U.S. Securities and Exchange Commission (SEC). The Company’s current commercialization strategy is targeted to countries where the Company can establish the market for its technology. This commercialization strategy will undergo continual prioritization and in the future the Company may adjust its commercialization efforts to preserve its existing cash or realize better results than anticipated which could have a positive impact on cash. The Company’s U.S. pivotal clinical trial and planned FDA approval is its highest priority. The Company must raise additional capital to fund its operations. It plans to raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements. Additional funds may not be available when the Company needs them on terms that are acceptable to the Company, or at all. If adequate funds are not available on acceptable terms, the Company may be required to delay, reduce the scope of, or curtail, its operations. To the extent that the Company raises additional funds by issuing equity securities, its shareholders will experience dilution, and debt financing, if available, may involve restrictive covenants.
Revenue Recognition	Revenue Recognition Prior to 2018, we recognized revenue when there is persuasive evidence that an arrangement exists with our customers, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Revenue was recognized upon shipment and payments are either received in advance, or net 30 days for lenses or net 14 days for accessories. Distributor arrangements included certain perfunctory acceptance provisions and a one-year warranty, from the date of shipment, that products are free from defects in material workmanship. Under such provisions customers may reject shipments via written notifications ranging from 14-45 days or exchange defective product under warranty for the same non-defective product. We have not had any significant rejected shipments or warranty claims. We did not grant price concessions to our distributors. In 2012, we changed our commercialization strategy from exclusively using distributors to also targeting refractive laser centers equipped with femtosecond lasers, except in countries that require the use of distributors or sales representatives. In December 2017, in light our re-ordering of operational priorities, we have focused our commercialization and clinical trial efforts outside of the U.S. in Germany and South Korea, including established ophthalmic clinics in those countries. We recognize revenue from laser centers and ophthalmic clinics based upon an analysis of the terms of each customer arrangement and upon determination that persuasive evidence of an arrangement exists, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Revenues from laser centers and ophthalmic clinics during the three and six months ended June 30, 2018 and 2017 were not material. Effective January 1, 2018, the Company adopted the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), using the modified retrospective transition method. Under this method, the Company recognizes revenue based on an analysis of the goods and services provided to our customers in the ordinary course. We analyze all commercial agreements to identify (i) contracts and arrangements with customers that meet the criteria for revenue recognition under the new standard (ii) identify all performance obligations under the contractual arrangement, such as the delivery of our Microlens to our customers and any other deliverable(s) as defined in a commercial arrangement (iii) the determination of the transaction price and the allocation of such pricing over the defined contractual obligations in the contract with the customer and (iv) the recognition of revenue once the customer has assumed control over the contractual obligations. Control refers to the ability on the part of the customer to obtain substantially all the benefits of possession of the delivered product or service.
Foreign Currency	Foreign Currency The functional currency of subsidiaries outside the United States of America is the U.S. Dollar. Transactions in foreign currencies during the year are re-measured at rates of exchange on the dates of the transactions. Gains and losses related to re-measurement of items arising through operating activities are accounted for in the statement of operations and comprehensive loss and included in general and administrative expense. Aggregate foreign exchange gains and losses are included in the Condensed Consolidated Statement of Operations. Aggregate foreign exchange gain was $28,000 for the three months ended June 30, 2018, and aggregate foreign exchange loss was $24,000 for the six months ended June 30, 2018. Aggregate foreign exchange loss was $52,000 and $79,000 for the three and six months ended June 30, 2017, respectively.
Comprehensive Loss	Comprehensive Loss Comprehensive income or loss is defined as a change in equity of a company attributable to all transactions excluding those transactions resulting from investment with owners and distributions to owners. There were no differences between net loss and comprehensive loss in the three and six months ended June 30, 2018 and 2017 .
Future Accounting Pronouncements	Future Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 will be effective for the Company in the first quarter of 2019. ASU 2016-02 will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Although the Company is currently evaluating the full impact of ASU 2016-02 on its consolidated financial statements, upon adoption of ASU 2016-02 the Company anticipates that its operating leases will be recognized on the balance sheet as a lease liability if certain criteria is met, with a corresponding right of use asset. In February 2018, the FASB issued ASU 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220)—Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. This update was issued to address the income tax accounting treatment of the stranded tax effects within other comprehensive income due to the prohibition of backward tracing due to an income tax rate change that was initially recorded in other comprehensive income. This issue came about from the enactment of the Tax Cuts and Jobs Act on December 22, 2017, which changed the Company’s income tax rate from 35% to 21%. The ASU changed current accounting whereby an entity may elect to reclassify the stranded tax effect from accumulated other comprehensive income to retained earnings. The ASU is effective for periods beginning after December 15, 2018, although early adoption is permitted. The Company does not anticipate that the adoption of this ASU will have a material impact on its consolidated financial statements. In June 2018, the FASB issued ASU No. 2018-07, Compensation — Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. The new standard expands the scope of Topic 718 to include all share-based payment transactions for acquiring goods and services from nonemployees. ASU No. 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which the grantor acquires goods and services to be used or consumed in its own operations by issuing share-based payment awards. ASU NO. 2018-07 also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under ASC 606. ASU No. 2018-07 will be effective for the Company beginning after December 15, 2019, with early adoption permitted, but no earlier than the Company’s adoption of ASC 606. The Company is currently assessing the potential impact of adopting this guidance on its consolidated financial statements.
Recent Accounting Standards	Recent Accounting Standards In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The new standard is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 became effective for the Company in the first quarter of 2018 and allowed for full retrospective or a modified retrospective adoption approach. The Company adopted this new standard in January 2018 and it did not have a material adjustment on its consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows In October 2016, the FASB issued ASU. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other than Inventory. In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting,

Loss per Share (Tables)

Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Schedule of Calculation of Basic and Diluted Loss per Share	Basic and diluted loss per share for the three and six months ended June 30, 2018 and 2017 were calculated as follows: Three-Months Ended June 30, Six-Months Ended June 30, 2018 2017 2018 2017 Net Loss $ (2,251 ) $ (4,533 ) $ (4,265 ) $ (9,125 ) Weighted average shares outstanding - basic and diluted 17,079,548 16,956,056 17,042,358 15,618,001 Net loss per ordinary share - basic and diluted $ (0.13 ) $ (0.27 ) $ (0.25 ) $ (0.58 )

Equity Based Awards (Tables)

Equity Based Awards (Tables)	6 Months Ended
	Jun. 30, 2018
Share-Based Compensation Expense Included in Consolidated Statements of Operations	The following table shows share-based compensation expense based upon all equity awards issued by Presbia PLC included in the Consolidated Statements of Operations for the three and six months ended June 30, 2018 and 2017. The Company recorded a credit of $86,000 and $524,000 as a result of the reversal of stock-based compensation for participants whose relationship with the Company terminated in the three and six months ended June 30, 2018, respectively. Three-Months Ended June 30, Six-Months Ended June 30, 2018 2017 2018 2017 Research and development $ (49 ) $ 126 $ (227 ) $ 242 General and administrative 174 311 175 641 Sales and marketing 30 78 60 155 $ 155 $ 515 $ 8 $ 1,038
Schedule of Option Activity	The following table sets forth the Company’s option activity for the six months ended June 30, 2018: Number of Presbia PLC Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance, January 1, 2018 849,100 $ 9.77 — Granted 365,000 $ 2.38 — Exercised — — — Forfeited/cancelled/expired (71,450 ) $ 9.38 — Balance, June 30, 2018 1,142,650 $ 7.44 — Vested, June 30, 2018 726,150 $ 9.82 — Non Vested, June 30, 2018 416,500 $ 3.27 — Exercisable, June 30, 2018 726,150 $ 9.82 —
Schedule of Restricted Shares Activity	The Company awarded 23,255 ordinary shares to the head of the Company’s medical advisory board as compensation for services provided during the six-month period ended June 30, 2018. The number of shares was determined by the closing price of $2.15 on June 29, 2018. The following table sets forth the Company’s restricted share activity for the three and six months ended June 30, 2018: Unvested Number of Shares Weighted Average Fair Value per Share Balance, December 31, 2017 134,367 $ 3.78 Granted 23,255 2.15 Vested (104,731 ) 3.02 Forfeited/cancelled — — Unvested, June 30, 2018 52,891 $ 5.45
Schedule of RSU Activity	The following table sets forth the Company’s RSU activity for the six months ended June 30, 2018: Unvested Number of Shares Weighted Average Fair Value per Share Balance, December 31, 2017 739,000 $ 2.09 Granted — — Vested — — Forfeited/cancelled (226,000 ) 2.44 Unvested, June 30, 2018 513,000 $ 1.32
Non-employee options [Member]
Schedule of Black-Scholes Valuation Model Assumptions for Estimating the Fair Value of Share-Based Compensation	During the three and six months ended June 30, 2018 and 2017, the Company did not grant options to non-employee consultants and medical advisors. In contrast to the determination of the fair value of options granted to employees, which are determined based upon the grant-date assumptions and applying the Black-Scholes model, the fair values for non-employee options and the related stock-based compensation expense are remeasured each financial reporting period based upon the assumptions applicable on the dates in which the financial statements are prepared, which are disclosed in the following table: Three-Months Ended June 30, Six-Months Ended June 30, 2018 2017 2018 2017 Stock price per share $0.85 - $1.13 $1.25 - $1.63 $0.85 - $1.95 $1.25 - $2.51 Expected term 6.6 - 7.1 Yrs. 7.7 - 8.4 Yrs 6.6 - 7.4 Yrs. 7.7 - 8.6 Yrs Volatility 72.9% - 77.3% 79.1% - 83.5% 72.9% - 77.3% 79.1% - 90.0% Dividends — — — — Risk-free rate 2.8% 2.2% 2.6% - 2.8% 2.2% - 2.3%

Income Taxes (Tables)

Income Taxes (Tables)	6 Months Ended
	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Schedule of Reconciliation of Gross Unrecognized Tax Benefits	A reconciliation of gross unrecognized tax benefits is as follows: June 30, 2018 December 31, 2017 Balance at the beginning of the year 199,000 — Increases related to current year tax positions 75,000 199,000 Balance at the end of the year $ 274,000 $ 199,000

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Accumulated deficit	$ 92,567	$ 88,302

Summary of Significant Accoun20

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Significant Accounting Policies [Line Items]
Warranty period, from the date of shipment			1 year
Income tax rate			21.00%		35.00%
General and Administrative Expense [Member]
Significant Accounting Policies [Line Items]
Aggregate foreign exchange gain (loss)	$ 28,000	$ (52,000)	$ (24,000)	$ (79,000)
Minimum [Member]
Significant Accounting Policies [Line Items]
Written notification period to reject shipments by customers			14 days
Maximum [Member]
Significant Accounting Policies [Line Items]
Written notification period to reject shipments by customers			45 days
Lenses [Member]
Significant Accounting Policies [Line Items]
Payments collection period			30 days
Accessories [Member]
Significant Accounting Policies [Line Items]
Payments collection period			14 days

Loss per Share - Schedule of Ca

Loss per Share - Schedule of Calculation of Basic and Diluted Loss per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Basic and diluted net loss per share
Net Loss	$ (2,251)	$ (4,533)	$ (4,265)	$ (9,125)
Weighted average shares outstanding - basic and diluted	17,079,548	16,956,056	17,042,358	15,618,001
Net loss per ordinary share - basic and diluted	$ (0.13)	$ (0.27)	$ (0.25)	$ (0.58)

Loss per Share - Additional Inf

Loss per Share - Additional Information (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Earnings Per Share [Abstract]
Antidilutive securities, not included in diluted net loss per calculation	1,049,795	1,152,500	972,019	1,050,000

Equity Based Awards - Additiona

Equity Based Awards - Additional Information (Detail) - USD ($)	Jan. 14, 2015	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation charge reversal		$ 86,000		$ 524,000
Options granted				365,000
Non-employee consultants and medical advisors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Options granted		0	0	0	0
Employee Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Awards vesting period		5 years		5 years
Award expiration period		6 years 9 months		6 years 9 months
Options granted		365,000	0	0	0
Medical Advisory Board Compensation [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock awarded for services				23,255
Closing price per share		$ 2.15		$ 2.15
Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Award expiration period				7 years
Authorized issuance percentage of each recipient’s total RSU award				20.00%
Consecutive trading days				20 days
Wait or service period				1 year
Unrecognized compensation expense, weighted average period of recognition				10 months 24 days	2 years 4 months 24 days
Unrecognized compensation expense related to restricted shares/RSUs		$ 513,000	$ 7,710,000	$ 513,000	$ 7,710,000
Restricted shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Unrecognized compensation expense, weighted average period of recognition				1 year 9 months 18 days	1 year 6 months
Unrecognized compensation expense related to restricted shares/RSUs		226,000	290,000	$ 226,000	$ 290,000
Employee and non-employee options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Unrecognized compensation expense related to options		$ 785,000	$ 2,740,000	$ 785,000	$ 2,740,000
Unrecognized compensation expense, weighted average period of recognition				2 years 3 months 18 days	1 year 8 months 12 days
Over five year period [Member] | Employee Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Generally vesting percentage for annual		20.00%		20.00%
Threshold Price Period 1 [Member] | Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share price threshold				$ 10
Threshold Price Period 2 [Member] | Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share price threshold				15
Threshold Price Period 3 [Member] | Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share price threshold				20
Threshold Price Period 4 [Member] | Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share price threshold				25
Threshold Price Period 5 [Member] | Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share price threshold				$ 30
Presbia Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Awards vesting period	5 years
Ordinary shares authorized for issuance	2,200,000
Ordinary shares available for future grants and awards		367,591		367,591
Award expiration period	10 years
Award expiration date				Jan. 14, 2025
Presbia Incentive Plan [Member] | Over five year period [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Generally vesting percentage for annual	20.00%

Equity Based Awards - Share-Bas

Equity Based Awards - Share-Based Compensation Expense Included in Consolidated Statements of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 155	$ 515	$ 8	$ 1,038
Research and development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	(49)	126	(227)	242
General and administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	174	311	175	641
Sales and marketing [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 30	$ 78	$ 60	$ 155

Equity Based Awards - Schedule

Equity Based Awards - Schedule of Option Activity (Detail) - $ / shares	6 Months Ended
	Jun. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Presbia PLC Shares, Beginning Balance	849,100
Number of shares, Granted	365,000
Number of Presbia PLC Shares, Forfeited/cancelled/expired	(71,450)
Number of Presbia PLC Shares, Ending Balance	1,142,650
Number of Presbia PLC Shares, Vested	726,150
Number of Presbia PLC Shares, Non Vested	416,500
Number of Presbia PLC Shares, Exercisable	726,150
Weighted Average Exercise Price Per Share, Beginning Balance	$ 9.77
Weighted Average Exercise Price Per Share, Granted	2.38
Weighted Average Exercise Price Per Share, Forfeited/cancelled/expired	9.38
Weighted Average Exercise Price Per Share, Ending Balance	7.44
Weighted Average Exercise Price Per Share, Vested	9.82
Weighted Average Exercise Price Per Share, Non Vested	3.27
Weighted Average Exercise Price Per Share, Exercisable	$ 9.82

Equity Based Awards - Schedul26

Equity Based Awards - Schedule of Black-Scholes Valuation Model Assumptions for Estimating the Fair Value of Share-Based Compensation (Detail) - Non-employee options [Member] - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Volatility minimum	72.90%	79.10%	72.90%	79.10%
Volatility maximum	77.30%	83.50%	77.30%	90.00%
Risk-free rate	2.80%	2.20%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock price per share	$ 0.85	$ 1.25	$ 0.85	$ 1.25
Expected term	6 years 7 months 6 days	7 years 8 months 12 days	6 years 7 months 6 days	7 years 8 months 12 days
Risk-free rate			2.60%	2.20%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock price per share	$ 1.13	$ 1.63	$ 1.95	$ 2.51
Expected term	7 years 1 month 6 days	8 years 4 months 24 days	7 years 4 months 24 days	8 years 7 months 6 days
Risk-free rate			2.80%	2.30%

Equity Based Awards - Schedul27

Equity Based Awards - Schedule of Restricted Share Activity (Detail) - Restricted shares [Member]	6 Months Ended
	Jun. 30, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Unvested Number of Shares, Beginning Balance | shares	134,367
Unvested Number of Shares, Granted | shares	23,255
Unvested Number of Shares, Vested | shares	(104,731)
Unvested Number of Shares, Ending Balance | shares	52,891
Weighted Average Fair Value per Share, Beginning Balance | $ / shares	$ 3.78
Weighted Average Fair Value per Share, Granted | $ / shares	2.15
Weighted Average Fair Value per Share, Vested | $ / shares	3.02
Weighted Average Fair Value per Share, Ending Balance | $ / shares	$ 5.45

Equity Based Awards - Schedul28

Equity Based Awards - Schedule of RSU Activity (Detail) - Restricted Share Units [Member]	6 Months Ended
	Jun. 30, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Unvested Number of Shares, Beginning Balance | shares	739,000
Unvested Number of Shares, Forfeited/cancelled | shares	(226,000)
Unvested Number of Shares, Ending Balance | shares	513,000
Weighted Average Fair Value per Share, Beginning Balance | $ / shares	$ 2.09
Weighted Average Fair Value per Share, Forfeited/cancelled | $ / shares	2.44
Weighted Average Fair Value per Share, Ending Balance | $ / shares	$ 1.32

Concentration of Credit Risk -

Concentration of Credit Risk - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2016
Concentration Risk [Line Items]
Cash	$ 3,328,000	$ 3,236,000	$ 10,668,000	$ 7,333,000
Supplier agreement term	5 years
Supplier agreement, expiration date	2017-01
Cost of Goods, Total [Member] | Supplier Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk percentage	100.00%
Federal Deposit Insurance Corporation [Member] | Maximum [Member]
Concentration Risk [Line Items]
Cash	$ 250,000

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax [Line Items]
Description of uncertain income tax position being recognized	An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.
Liability for unpaid irish income taxes	$ 274,000	$ 199,000	$ 0
Accrued interest and penalties	35,000	39,000
Foreign [Member] | Ireland [Member]
Income Tax [Line Items]
Liability for unpaid irish income taxes	$ 274,000	$ 199,000

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Gross Unrecognized Tax Benefits (Detail) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Balance at the beginning of the year	$ 199,000	$ 0
Increases related to current year tax positions	75,000	199,000
Balance at the end of the year	$ 274,000	$ 199,000

Equity Transaction with Relat32

Equity Transaction with Related Party - Additional Information (Detail) - USD ($)	Apr. 12, 2018	Jun. 30, 2018	Jun. 30, 2018
Related Party Transaction [Line Items]
Number of preferred shares with undeclared dividends		50,334
Preferred shares description			As long as the preferred shares remain outstanding, neither the Company nor its subsidiary shall take the following actions, without obtaining the prior consent of the holder of the preferred shares: (a) effect any alteration, repeal, change or amendment of the rights, privileges or preferences of the preferred shares in a manner that adversely affects the rights, privileges or preferences of those shares or any series thereof; (b) amend, modify or repeal any provision of the organizational documents in a manner that adversely affects the powers, preferences or rights of the preferred shares; (c) agree to any debt financing in an amount in excess of $8,000,000 (such amount being the maximum amount payable by the company under the debt instruments); (d) execute a guarantee; (e) effect any restructuring or liquidation; (f) settle any lawsuit or civil investigation requiring the payment of more than $1,000,000; or (g) execute any document or enter into any arrangement that has a potential liability to the Company in excess of $1,000,000.
Debt financing threshold	$ 8,000,000
Legal settlement threshold	1,000,000
Potential liability under arrangment threshold	$ 1,000,000
First 18 Months [Member]
Related Party Transaction [Line Items]
Preferred shares dividend rate	10.00%
19 through 24 Months [Member]
Related Party Transaction [Line Items]
Preferred shares dividend rate	20.00%
Month 25 and Thereafter [Member]
Related Party Transaction [Line Items]
Preferred shares dividend rate	30.00%
Richard Ressler [Member]
Related Party Transaction [Line Items]
Ordinary shares called by warrants	1,953,125
Exercise price	$ 2.56
Warrant exercisable period	5 years
Richard Ressler [Member] | Preferred Shares [Member] | Private Placement [Member]
Related Party Transaction [Line Items]
Preferred shares aggregate purchase price	$ 5,000,000
Richard Ressler [Member] | Preferred Shares [Member] | Private Placement [Member] | Presbia PLC [Member]
Related Party Transaction [Line Items]
Preferred shares issued	100
Richard Ressler [Member] | Preferred Shares [Member] | Private Placement [Member] | Presbia USA, Inc [Member]
Related Party Transaction [Line Items]
Preferred shares issued	4,900

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Jun. 01, 2016	Jan. 02, 2016	Dec. 01, 2013	May 31, 2012	Dec. 31, 2017USD ($)Facility	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Dec. 31, 2017USD ($)
Commitments And Contingencies [Line Items]
Rent expense						$ 113,000	$ 168,000	$ 208,000	$ 337,000
California [Member]
Commitments And Contingencies [Line Items]
Lease period				5 years
Lease expiration period	May 31, 2022			May 31, 2017
Lease renewal term	5 years
Ireland [Member]
Commitments And Contingencies [Line Items]
Lease period			1 year
Lease renewal term			1 month
Lease commencement date			Dec. 1, 2013
The Netherlands [Member]
Commitments And Contingencies [Line Items]
Lease period		30 months
Lease commencement date		Jan. 1, 2016
Lease termination period		2018-02
Reorganization [Member] | California [Member]
Commitments And Contingencies [Line Items]
Number of facilities vacated | Facility					1
Fair value of remaining lease obligation					$ 222,000					$ 222,000
Vacated facility remaining lease term										33 months